Bpc-157 | C62H98N16O22 | CID 9941957
US$ 20.45
ipamorelin / cjc-1295 No DAC + 10mg CJC-1295 + Ipamorelin
Description
AM-R, DS-R, and CB-O: writingoriginal draft preparation
It is preferable not to mix other drugs with the Viscotin solution
(3) Persistence adds valuable information
The compound was developed in the late 1990s by Novo Nordisk and characterised in a 1998 paper as the first selective GH secretagogue, meaning it stimulated GH release without the prolactin, ACTH, cortisol, or aldosterone elevations seen with earlier GHRPs
Breast Cancer Res Treat 2012;132(1):175187
